• Publications
  • Influence
Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
Blood glucose control is the primary strategy to prevent complications in diabetes. At the onset of kidney disease, therapies that inhibit components of the renin angiotensin system (RAS) are alsoExpand
  • 73
  • 4
  • PDF
Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
This Article contains errors in the Acknowledgements section. " The authors acknowledge funding support from the National Health and Medical Council of Australia (1004926). " should read: " TheExpand
  • 1